AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
Rhea-AI Summary
AtaiBeckley (NASDAQ: ATAI) reported Q4 and full-year 2025 results and clinical updates on March 6, 2026. Key clinical milestones include a successful FDA End-of-Phase 2 meeting for BPL-003 and Phase 3 initiation targeted for Q2 2026, VLS-01 Phase 2 topline readout expected in H2 2026, and positive Phase 2a EMP-01 SAD results. Financially, cash and short-term securities totaled $220.7M at year-end and management expects runway into early 2029. The company completed a strategic combination and U.S. redomiciliation in late 2025.
Positive
- Phase 3 initiation for BPL-003 on track for Q2 2026
- Cash, cash equivalents and short-term securities of $220.7M
- Company expects capital to fund operations into early 2029
- EMP-01 Phase 2a showed LSAS −11.85 placebo-adjusted improvement
- U.S. patent for EMP-01 extending exclusivity through 2043
Negative
- Net loss attributable to stockholders of $660.0M for FY2025
- Non-cash in‑process R&D expense of $530.0M in 2025
- G&A expenses increased to $65.1M for FY2025
- Used $102.7M in operations during 2025
News Market Reaction – ATAI
On the day this news was published, ATAI declined 4.24%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $57M from the company's valuation, bringing the market cap to $1.29B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ATAI traded down 4.07% while several biotech peers like QURE (+17.81%) and ATNF (+2.92%) moved higher, suggesting a stock-specific reaction rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Positive | -2.3% | Reported Q3 2025 results, BPL-003 BTD, funding into 2029, $150M raise. |
| Aug 14 | Q2 2025 earnings | Positive | -1.0% | Q2 2025 results, positive BPL-003 Phase 2b data, funding into H2 2027. |
| May 14 | Q1 2025 earnings | Positive | +1.4% | Q1 2025 results, strengthened cash to $108.2M, pipeline trial progress. |
| Mar 17 | FY 2024 results | Positive | -1.4% | FY 2024 update, equity raise extending runway to 2027 and clinical advances. |
| Nov 13 | Q3 2024 earnings | Positive | -7.5% | Q3 2024 results, VLS-01 IND clearance, EMP-01 and VLS-01 plans. |
Earnings and financial updates have typically been followed by modestly negative price moves despite generally constructive clinical and funding news.
Over the last five earnings or financial result updates from Nov 2024 to Nov 2025, AtaiBeckley consistently paired clinical pipeline progress in TRD and social anxiety with capital raises that extended runway into 2027–2029. Yet, four of these five events saw negative next-day moves, yielding an average move of about -2.14%. Today’s Q4 and full-year 2025 results continue the theme of strengthened liquidity and advancing BPL-003, VLS-01, and EMP-01 programs.
Historical Comparison
Past five earnings or annual updates averaged a -2.14% move. Today’s -4.07% pre-news decline is somewhat larger but directionally consistent with the historical pattern.
Across recent earnings cycles, the company repeatedly combined trial progress in BPL-003, VLS-01, and EMP-01 with equity financings that extended runway from 2026 out to 2029, while moving BPL-003 from earlier phases toward a Phase 3 program.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration dated September 29, 2025, used via multiple 424B prospectus supplements. This provides flexibility to register and resell securities, which can facilitate future capital access but may introduce dilution when utilized.
Market Pulse Summary
This announcement combines Q4 and full-year 2025 results with meaningful progress in BPL-003, VLS-01, and EMP-01, and guides cash runway into 2029. Historical earnings releases often coincided with fundraising and trial advancement, while near-term catalysts include Phase 3 initiation and multiple 2026 readouts. Investors may focus on the scale of non-cash IPR&D charges, net loss trends, and how actively the existing S-3ASR shelf is utilized.
Key Terms
phase 3 medical
madrs medical
liebowitz social anxiety scale medical
cgi-i medical
number needed to treat medical
end‑of‑phase 2 regulatory
nda regulatory
open-label extension medical
AI-generated analysis. Not financial advice.
- Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration
- On-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026
- Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measures
- Cash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studies
- Virtual Investor Day scheduled for March 6, 2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced fourth quarter and full year 2025 financial results and provided key regulatory, clinical and business updates.
“Following our strategic combination of atai Life Sciences and Beckley Psytech, and U.S. redomiciliation, we have entered a pivotal execution phase,” said Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-Founder of AtaiBeckley. “We received constructive feedback from the FDA on the Phase 3 development plan for BPL-003 in treatment-resistant depression, positioning us to initiate our pivotal program in the second quarter of 2026. We also reported positive topline results from our exploratory Phase 2a study of EMP-01 in Social Anxiety Disorder, which met its primary safety objective and demonstrated clinically meaningful improvements across key efficacy measures after just two administrations and without adjunct psychotherapy. With multiple clinical catalysts ahead and capital expected to fund operations into 2029, we believe AtaiBeckley is well positioned to advance a differentiated portfolio of rapid-acting mental health therapies.”
Program Updates and Anticipated Milestones
BPL-003: mebufotenin benzoate nasal spray for TRD
- In March 2026, the Company announced a successful End‑of‑Phase 2 meeting with the FDA regarding the development of BPL‑003 for treatment‑resistant depression (TRD), a debilitating and chronic condition affecting millions of people around the world but with limited rapid-acting treatment options.
- The FDA indicated support for advancement into Phase 3 studies in adults with TRD and provided constructive feedback on the overall design and requirements for a potential NDA package for this indication.
- The Phase 3 program is designed to include two pivotal studies, ReConnection-1 and ReConnection-2, each consisting of a 12-week, randomized, double-blind, placebo-controlled core study followed by a 52-week open-label extension (OLE):
- ReConnection-1:
- Approximately 350 participants
- Single-dose of BPL-003 across three treatment arms - 8 mg, 4 mg, and placebo (randomized 2:1:2)
- Designed to replicate and extend Phase 2b treatment response and further characterize dose–response relationship for BPL-003
- ReConnection-2:
- Approximately 300 participants
- Two-dose design (Day 1 and Day 15) across two arms - 8 mg BPL-003 and placebo (randomized 1:1)
- Designed to evaluate if a two-dose induction model increases magnitude and durability of initial response
- ReConnection-1:
- The primary endpoint in both pivotal trials will be the change from baseline in the MADRS total score at Week 4.
- Both trials include a 52-week OLE allowing individualized 8 mg BPL-003 retreatment at 8- or 12-week intervals with the aim of maintaining remission.
- Phase 3 program initiation remains on track for Q2 2026.
- Topline data from the core studies of both ReConnection-1 and –2 anticipated by early 2029.
- First patient dosed in the Part 4 cohort of the open-label Phase 2a study, evaluating a two-dose induction regimen (8 mg + 8 mg) of BPL-003 in TRD patients receiving defined antidepressants. Initial data expected in Q4 2026.
VLS-01: dimethyltryptamine (DMT) buccal film for TRD
- VLS-01 is an investigational proprietary oral transmucosal film formulation of DMT applied to the buccal surface, designed to fit within the established two-hour interventional psychiatry treatment paradigm.
- Phase 2 Elumina study topline data readout is anticipated in H2 2026.
EMP-01: Oral R-enantiomer of 3,4-methylenedioxy-methamphetamine (R-MDMA) for social anxiety disorder (SAD)
- In February 2026, the Company reported topline results from the exploratory, randomized, double‑blind, placebo‑controlled Phase 2a trial of EMP‑01 in SAD:
- Key findings:
- Met primary safety and tolerability objective with a generally favorable and manageable profile
- Clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)
49% responder rate on Clinician Global Impression–Improvement (CGI-I) vs.15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95- Demonstrated improvements across Fear and Avoidance sub-domains of LSAS
- Key findings:
- In December 2025, the Company was granted a new U.S. patent covering the EMP‑01 drug substance, extending expected exclusivity through 2043.
- More detailed analyses of the data will be described in upcoming scientific venues and are expected to inform next development steps.
Business Highlights
- Completed the strategic combination in November 2025 between atai Life Sciences N.V. and Beckley Psytech Limited, creating AtaiBeckley, a global leader in transformative mental health therapies.
- Completed the redomiciliation to the United States in December 2025 as a Delaware‑incorporated company with headquarters in New York, NY.
- AtaiBeckley Inc. was added to the NASDAQ Biotechnology Index (NBI) in December 2025.
- The Company will host a Virtual Investor Day on March 6, 2026, centered on BPL‑003 and the Phase 3 development strategy.
- The Virtual Investor Day will feature:
- Detailed overview of the BPL-003 Phase 3 program
- Discussion of the commercial opportunity in treatment-resistant depression
- Key opinion leader roundtable discussing the evolving psychedelic therapeutic landscape and operational considerations in interventional psychiatry
Upcoming Anticipated Milestones and Events
- March 6, 2026: Virtual Investor Day
- Q2 2026: Initiation of BPL-003 Phase 3 ReConnection-1 and ReConnection-2 trials
- H2 2026: Topline data from VLS-01 Elumina Phase 2 study
- Q4 2026: Initial data from Phase 2a BPL-003 Part 4 cohort
Consolidated Financial Results
Cash, cash equivalents, and short-term securities (primarily US treasuries): As of December 31, 2025, the Company had cash, cash equivalents and short-term securities of
Research and development (R&D) expenses: R&D expenses were
We recorded non-cash acquisition of in-process R&D expenses of
General and administrative (G&A) expenses: G&A expenses for the three and twelve months ended December 31, 2025, were
Net income (loss): Net loss attributable to stockholders for the three and twelve months ended December 31, 2025, was
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company with a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new breakthroughs in mental health by providing transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones and the outcome of related regulatory discussions; expectations regarding our intellectual property portfolio; expectations regarding our cash runway; and the plans and objectives of management for future operations, research and development and capital expenditures.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) or Quarterly Reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in our other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com
Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com
-- Financial Statements Attached –
| ATAIBECKLEY INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (Amounts in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| (unaudited) | ||||||||||||||||
| Revenue | $ | 1,066 | $ | (5 | ) | $ | 4,089 | $ | 308 | |||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 18,962 | 18,942 | 53,062 | 55,455 | ||||||||||||
| Acquisition of in-process research and development | 527,000 | — | 530,000 | — | ||||||||||||
| General and administrative | 25,086 | 11,318 | 65,088 | 47,544 | ||||||||||||
| Total operating expenses | 571,048 | 30,260 | 648,150 | 102,999 | ||||||||||||
| Loss from operations | (569,982 | ) | (30,265 | ) | (644,061 | ) | (102,691 | ) | ||||||||
| Other income (expense), net | 25,062 | (8,919 | ) | (15,788 | ) | (45,714 | ) | |||||||||
| Net loss before income taxes | (544,920 | ) | (39,184 | ) | (659,849 | ) | (148,405 | ) | ||||||||
| Benefit from (provision for) income taxes | 82 | 193 | (298 | ) | 356 | |||||||||||
| Losses from investments in equity method investees, net of tax | — | — | — | (2,000 | ) | |||||||||||
| Net loss | (544,838 | ) | (38,991 | ) | (660,147 | ) | (150,049 | ) | ||||||||
| Net loss attributable to noncontrolling interests | (25 | ) | (33 | ) | (100 | ) | (780 | ) | ||||||||
| Net loss attributable to AtaiBeckley Inc. stockholders | $ | (544,813 | ) | $ | (38,958 | ) | $ | (660,047 | ) | $ | (149,269 | ) | ||||
| Net loss per share attributable to AtaiBeckley Inc. stockholders — basic and diluted | $ | (1.73 | ) | $ | (0.24 | ) | $ | (2.91 | ) | $ | (0.93 | ) | ||||
| Weighted average common shares outstanding attributable to AtaiBeckley Inc. stockholders — basic and diluted | 314,276,378 | 160,711,543 | 226,532,786 | 160,159,983 | ||||||||||||
| ATAIBECKLEY INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEET | ||||||||
| (Amounts in thousands) | ||||||||
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 85,300 | $ | 17,505 | ||||
| Securities carried at fair value | 135,351 | 44,825 | ||||||
| Short-term restricted cash for other investments | — | 10,000 | ||||||
| Other current investments held at fair value | 35,389 | — | ||||||
| Prepaid expenses and other current assets | 19,644 | 7,795 | ||||||
| Property and equipment, net | 2,166 | 2,535 | ||||||
| Operating lease right-of-use assets, net | 1,846 | 1,334 | ||||||
| Other investments held at fair value | — | 28,887 | ||||||
| Other investments | — | 42,079 | ||||||
| Intangible assets, net | 2,851 | 3,246 | ||||||
| Goodwill | 331 | 331 | ||||||
| Digital assets | 8,735 | — | ||||||
| Other assets | 1,110 | 850 | ||||||
| Total assets | $ | 292,723 | $ | 159,387 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Accounts payable | $ | 4,906 | $ | 2,616 | ||||
| Accrued liabilities | 14,168 | 9,847 | ||||||
| Current portion of lease liabilities | 271 | 477 | ||||||
| Short-term convertible promissory notes and derivative liability - related party | — | 1,150 | ||||||
| Short-term convertible promissory notes and derivative liability | — | 1,840 | ||||||
| Current portion of long-term debt | — | 6,374 | ||||||
| Deferred revenue | 1,524 | 721 | ||||||
| Other current liabilities | 2,610 | 1,926 | ||||||
| Contingent consideration liability - related party | 104 | 110 | ||||||
| Contingent consideration liabilities | 205 | 212 | ||||||
| Noncurrent portion of lease liabilities | 1,801 | 732 | ||||||
| Pre-funded warrant liabilities | 44,379 | — | ||||||
| Long-term debt, net | — | 14,133 | ||||||
| Other liabilities | 754 | 2,695 | ||||||
| Total stockholders’ equity attributable to AtaiBeckley Inc. stockholders | 221,874 | 116,297 | ||||||
| Noncontrolling interests | 127 | 257 | ||||||
| Total liabilities and stockholders' equity | $ | 292,723 | $ | 159,387 | ||||
FAQ
When will ATAI start Phase 3 trials for BPL-003 in treatment-resistant depression?
How long is AtaiBeckley’s cash runway after the 2025 results (ATAI)?
What were the top-line Phase 2a results for EMP-01 in social anxiety disorder (ATAI)?
What financial impacts from the Beckley Psytech combination affected ATAI’s 2025 results?
When can investors expect clinical readouts for ATAI’s VLS-01 and BPL-003 programs?
